Načítá se...
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
OBJECTIVES: To review published cost-effectiveness analyses (CEA) assessing bortezomib (BTZ) for multiple myeloma (MM) and explore possible bias affecting the cost-effectiveness of BTZ. METHODS: Literature was searched for published CEAs assessing BTZ or BTZ-containing regimens for MM from 2003 to 2...
Uloženo v:
| Vydáno v: | Clinicoecon Outcomes Res |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861606/ https://ncbi.nlm.nih.gov/pubmed/27217786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S104195 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|